UK Markets closed

Angion Biomedica Corp. (ANGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.2800+0.0400 (+3.23%)
At close: 04:00PM EDT
1.2800 -0.02 (-1.54%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 316.0350
52-week low 31.0750
50-day moving average 31.7449
200-day moving average 34.6661

Share statistics

Avg vol (3-month) 390.19k
Avg vol (10-day) 3128.71k
Shares outstanding 529.96M
Implied shares outstanding 6N/A
Float 821.64M
% held by insiders 127.35%
% held by institutions 123.32%
Shares short (28 Apr 2022) 4649.47k
Short ratio (28 Apr 2022) 48.15
Short % of float (28 Apr 2022) 42.55%
Short % of shares outstanding (28 Apr 2022) 42.17%
Shares short (prior month 30 Mar 2022) 4494.51k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021


Profit margin -192.76%
Operating margin (ttm)-138.84%

Management effectiveness

Return on assets (ttm)-34.15%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)28.31M
Revenue per share (ttm)1.00
Quarterly revenue growth (yoy)5,551.60%
Gross profit (ttm)-20.82M
EBITDA -39.22M
Net income avi to common (ttm)-54.57M
Diluted EPS (ttm)-4.0040
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)88.76M
Total cash per share (mrq)2.96
Total debt (mrq)4.66M
Total debt/equity (mrq)5.72
Current ratio (mrq)8.08
Book value per share (mrq)2.15

Cash flow statement

Operating cash flow (ttm)-52.64M
Levered free cash flow (ttm)-22.72M